Lucerastat, an Iminosugar for Substrate Reduction Therapy: Pharmacokinetics, Tolerability, and Safety in Subjects With Mild, Moderate, and Severe Renal Function Impairment

Journal of Clinical Pharmacology

Volumn 57, Issue 11, 2017, Pages 1425-1431

  Guérard, Nicolas ^a   Zwingelstein, Christian ^a   Dingemanse, Jasper ^a  

^a ACTELION PHARMACEUTICALS LTD   (Switzerland)

Author keywords

iminosugar; lucerastat; pharmacokinetics; renal function impairment; substrate reduction therapy

Indexed keywords

LUCERASTAT; OGT 923; 1 DEOXYNOJIRIMYCIN; MIGALASTAT;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; MILD RENAL IMPAIRMENT; MODERATE RENAL IMPAIRMENT; OPEN STUDY; PHASE 1 CLINICAL TRIAL; SEVERE RENAL IMPAIRMENT; TIME TO MAXIMUM PLASMA CONCENTRATION; ANALOGS AND DERIVATIVES; ANIMAL; CLINICAL TRIAL; DOG; HALF LIFE TIME; KIDNEY; KIDNEY FAILURE; METABOLISM; MIDDLE AGED; PROSPECTIVE STUDY; RAT; YOUNG ADULT;

1-DEOXYNOJIRIMYCIN; ADULT; AGED; ANIMALS; AREA UNDER CURVE; DOGS; FEMALE; HALF-LIFE; HUMANS; KIDNEY; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RATS; RENAL INSUFFICIENCY; YOUNG ADULT;

EID: 85021253598     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.944     Document Type: Article

References (17)

1. Thomas AS, Hughes DA. Fabry disease. Pediatr Endocrinol Rev. 2014;12(suppl 1):88–101.
2. Germain DP. Fabry disease. Orphanet J Rare Dis. 2010;5:30. https://doi.org/10.1186/1750-1172-5-30.
3. MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet. 2001;38(11):769–775.
4. MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet. 2001;38(11):750–760.
5. Schiffmann R. Fabry disease. Pharmacol Ther. 2009;122(1):65–77. https://doi.org/10.1016/j.pharmthera.2009.01.003.
6. Cox TM, Amato D, Hollak CE, et al. Evaluation of miglustat as maintenance therapy after enzyme therapy in adults with stable type 1 Gaucher disease: a prospective, open-label non-inferiority study. Orphanet J Rare Dis. 2012;7:102–116. https://doi.org/10.1186/1750-1172-7-102.
7. Germain DP, Hughes DA, Nicholls K, et al. Treatment of Fabry's disease with the pharmacologic chaperone migalastat. N Engl J Med. 2016;375(6):545–555. https://doi.org/10.1056/NEJMoa1510198.
8. Aerts JM, Hollak CE, Boot RG, Groener JE, Maas M. Substrate reduction therapy of glycosphingolipid storage disorders. J Inherit Metab Dis. 2006;29(2–3):449–456. https://doi.org/10.1007/s10545-006-0272-5.
9. Andersson U, Smith D, Jeyakumar M, et al. Improved outcome of N-butyldeoxygalactonojirimycin-mediated substrate reduction therapy in a mouse model of Sandhoff disease. Neurobiol Dis. 2004;16(3):506–515. https://doi.org/10.1016/j.nbd.2004.04.012.
10. Baek RC, Kasperzyk JL, Platt FM, Seyfried TN. N-Butyldeoxygalactonojirimycin reduces brain ganglioside and GM2 content in neonatal Sandhoff disease mice. Neurochem Int. 2008;52(6):1125–1133. https://doi.org/10.1016/j.neuint.2007.12.001.
11. Guerard N, Frey A, Zwingelstein C, Dingemanse J. Lucerastat, an iminosugar for substrate reduction therapy: pharmacokinetics, tolerability, and safety in subjects with mild, moderate, and severe renal function impairment. 5th Update on Fabry Nephropathy Symposium, Mexico City, Mexico, 2017, April 25–27. Nephron. 2017;136:172–173.
12. Guerard N, Morand O, Dingemanse J. Lucerastat, an iminosugar with potential as substrate reduction therapy for glycolipid storage disorders: safety, tolerability, and pharmacokinetics in healthy subjects. Orphanet J Rare Dis. 2017;12(1):9. https://doi.org/10.1186/s13023-017-0565-9.
13. Branton MH, Schiffmann R, Sabnis SG, et al. Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course. Medicine. 2002;81(2):122–138.
14. CDER, FDA. Guidance for Industry Pharmacokinetics in Patients with Impaired Renal Function—Study Design, Data Analysis, and Impact on Dosing and Labeling. 2010. https://doi.org/www.fda.gov/drugs/guidancecomplianceregulatoryinformation/guidances/ucm064982.htm. Accessed May 17, 2017.
15. Hettmansperger TP, McKean JW. Robust Nonparametric Statistical Methods. Boca Raton, FL: CRC Press; 2011.
16. Vanholder R, Van Landschoot N, De Smet R, Schoots A, Ringoir S. Drug protein binding in chronic renal failure: evaluation of nine drugs. Kidney Int. 1988;33(5):996–1004.
17. Guerard N, Oder D, Nordbeck P, et al. Lucerastat, an iminosugar for substrate reduction therapy: safety, tolerability, pharmacodynamics, and pharmacokinetics in adult subjects with Fabry disease. 5th Update on Fabry Nephropathy Symposium, Mexico City, Mexico, 2017, April 25–27, 2017. Nephron 2017;136:172–173.